
News|Articles|May 28, 2024
Accelerating Therapies With Curia From Conception to Manufacturing
Author(s)Curia
Partnering with a CDMO can help streamline drug development, and certain preparations can help ensure a successful collaboration. Scott Alderucci, Curia’s Director of Process Development, explores the advantages of partnering with a CDMO to navigate the journey from molecule conception to clinical trials, including the expertise, experience, and preparedness that a CDMO brings to the table.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
3
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
